These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 1451723)

  • 21. Influence of renal function on the pharmacokinetics of ramipril (HOE 498).
    Debusmann ER; Pujadas JO; Lahn W; Irmisch R; Jané F; Kuan TS; Mora J; Walter U; Eckert HG; Hajdú P
    Am J Cardiol; 1987 Apr; 59(10):70D-78D. PubMed ID: 3034037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Changes in serum and urinary myo-inositol levels in chronic glomerulonephritis.
    Pitkänen E
    Clin Chim Acta; 1976 Sep; 71(3):461-8. PubMed ID: 971534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nifedipine: influence of renal function on pharmacokinetic/hemodynamic relationship.
    Kleinbloesem CH; van Brummelen P; van Harten J; Danhof M; Breimer DD
    Clin Pharmacol Ther; 1985 May; 37(5):563-74. PubMed ID: 3987180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High-dose methylprednisolone sodium succinate (pulse therapy) in the treatment of renal disease: plasma and urine concentrations.
    Searle M; Lawson G; Chakraborty J; Baylis EM; Lee HA; Marks V
    Eur J Clin Pharmacol; 1985; 28(3):245-8. PubMed ID: 3891379
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clearance ratios of amylase and isoamylase to creatinine in renal disease.
    Pasternack A; Klockars M
    Clin Nephrol; 1978 Jan; 9(1):25-8. PubMed ID: 630741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radioimmunoassay of plasma and urinary gonadotrophins (FSH and LH) in subjects with impaired renal function.
    Fraioli F; D'Ottavio G; Conte D; Isidori A
    Folia Endocrinol; 1973 Feb; 26(1):1-7. PubMed ID: 4739851
    [No Abstract]   [Full Text] [Related]  

  • 27. [Relationship between nonalcoholic fatty liver disease markers and renal function in patients with type 1 diabetes].
    Bulum T; Duvnjak L
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():6-10. PubMed ID: 23120807
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers.
    Gillen M; Valdez S; Zhou D; Kerr B; Lee CA; Shen Z
    Drug Des Devel Ther; 2016; 10():3555-3562. PubMed ID: 27843295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function.
    Aweeka F; Jayesekara D; Horton M; Swan S; Lambrecht L; Wilner KD; Sherwood J; Anziano RJ; Smolarek TA; Turncliff RZ
    Br J Clin Pharmacol; 2000; 49 Suppl 1(Suppl 1):27S-33S. PubMed ID: 10771451
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative urinary protein excretion in chronic renal failure.
    McMorrow RG; Galla JH; Luke RG
    Am J Nephrol; 1982; 2(4):208-12. PubMed ID: 7148893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Urinary epidermal growth factor excretion is correlated to renal function loss per se and not to the degree of diabetic renal failure.
    ter Meulen CG; Bilo HJ; van Kamp GJ; Gans RO; Donker AJ
    Neth J Med; 1994 Jan; 44(1):12-7. PubMed ID: 8202200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety and efficacy of fluvastatin in hyperlipidemic patients with chronic renal disease.
    Yasuda G; Kuji T; Hasegawa K; Ogawa N; Shimura G; Ando D; Umemura S
    Ren Fail; 2004 Jul; 26(4):411-8. PubMed ID: 15462110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics and absolute bioavailability of carteolol, a new beta-adrenergic receptor blocking agent.
    Ishizaki T; Ohnishi A; Sasaki T; Kushida K; Horai Y; Chiba K; Suganuma T
    Eur J Clin Pharmacol; 1983; 25(1):95-101. PubMed ID: 6137389
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of sulpiride after intravenous administration in patients with impaired renal function.
    Bressolle F; Brès J; Mourad G
    Clin Pharmacokinet; 1989 Nov; 17(5):367-73. PubMed ID: 2582694
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
    Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cystatin C measurement and its practical use in patients with various renal diseases.
    Tian S; Kusano E; Ohara T; Tabei K; Itoh Y; Kawai T; Asano Y
    Clin Nephrol; 1997 Aug; 48(2):104-8. PubMed ID: 9285147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elimination of amphotericin B in impaired renal function.
    Morgan DJ; Ching MS; Raymond K; Bury RW; Mashford ML; Kong B; Sabto J; Gurr FW; Somogyi AA
    Clin Pharmacol Ther; 1983 Aug; 34(2):248-53. PubMed ID: 6872420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.
    Schunkert H; Kindler J; Gassmann M; Lahn W; Irmisch R; Ritz E; Debusmann ER; Pujadas JO; Koch KM; Sieberth HG
    Eur J Clin Pharmacol; 1989; 37(3):249-56. PubMed ID: 2533075
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DNA fragmentation in chronic glomerulonephritis: an immunohistological analysis.
    Ott U; Aschoff A; Pocock J; Fünfstück R; Jirikowski G; Stein G; Wolf G
    Nephron Clin Pract; 2007; 105(1):c18-28. PubMed ID: 17114899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.